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Targeting arginase-II protects mice 
from high-fat-diet-induced hepatic 
steatosis through suppression of 
macrophage inflammation
Chang Liu1, Angana G. Rajapakse1, Erwin Riedo2, Benoit Fellay2, Marie-Claire Bernhard3, 
Jean-Pierre Montani1,4, Zhihong Yang1,4 & Xiu-Fen Ming1,4
Nonalcoholic fatty liver disease (NAFLD) associates with obesity and type 2 diabetes. Hypoactive 
AMP-activated protein kinase (AMPK), hyperactive mammalian target of rapamycin (mTOR) signaling, 
and macrophage-mediated inflammation are mechanistically linked to NAFLD. Studies investigating 
roles of arginase particularly the extrahepatic isoform arginase-II (Arg-II) in obesity-associated NAFLD 
showed contradictory results. Here we demonstrate that Arg-II−/− mice reveal decreased hepatic 
steatosis, macrophage infiltration, TNF-α and IL-6 as compared to the wild type (WT) littermates 
fed high fat diet (HFD). A higher AMPK activation (no difference in mTOR signaling), lower levels of 
lipogenic transcription factor SREBP-1c and activity/expression of lipogenic enzymes were observed in 
the Arg-II−/− mice liver. Moreover, release of TNF-α and IL-6 from bone marrow-derived macrophages 
(BMM) of Arg-II−/− mice is decreased as compared to WT-BMM. Conditioned medium from Arg-II−/− 
-BMM exhibits weaker activity to facilitate triglyceride synthesis paralleled with lower expression of 
SREBP-1c and SCD-1 and higher AMPK activation in hepatocytes as compared to that from WT-BMM. 
These effects of BMM conditioned medium can be neutralized by neutralizing antibodies against TNF-α 
and IL-6. Thus, Arg-II-expressing macrophages facilitate diet-induced NAFLD through TNF-α and IL-6 in 
obesity.
Nonalcoholic fatty liver disease (NAFLD) referred to as an intracellular accumulation of triglycerides in the liver 
(steatosis) with or without hepatitis can lead to liver fibrosis and cirrhosis and may contribute to development 
and progression of the most important chronic complications of diabetes, including cardiovascular disease and 
chronic kidney disease1,2. NAFLD is commonly associated with obesity, insulin resistance and type 2 diabe-
tes3. Under the metabolic disorder conditions, hepatic de novo lipogenesis is paradoxically augmented despite 
insulin resistance4,5, which involves various mechanisms including activation of mammalian target of rapamy-
cin complex 1 - small ribosomal protein S6 kinase 1 (mTORC1-S6K1) signaling and inhibition of 5′ adenosine 
monophosphate-activated protein kinase (AMPK) pathway, leading to up-regulation and activation of hepatic 
sterol regulatory element-binding protein-1c (SREBP-1c)4–7. SREBP-1c is a master transcription factor regulat-
ing expression of various enzymes in the lipogenesis pathway such as malic enzyme (ME), glucose-6-phosphate 
dehydrogenase (G6PDH), acetyl-CoA carboxylase-1 (ACC1), fatty acid synthase (FAS), and stearoyl-CoA 
desaturase-1 (SCD-1)8. While mTORC1 pathway has been shown to induce SREBP-1c and promote hepatic lipo-
genesis5,9, activation of AMPK pathway e.g., by the antidiabetic drug metformin and thiazolidinediones, accounts 
for its therapeutic effects on liver steatosis through inhibition of SREBP-1c7,10,11.
It is well recognized that obesity and inflammation are highly integrated processes in the pathogenesis of 
insulin resistance, type 2 diabetes and NAFLD12. Macrophages are heterogeneous and two extreme phenotypes, 
i.e., pro-inflammatory M1 and anti-inflammatory M2, are the most well investigated13. Macrophage infiltration 
accompanied by inflammation and metabolic alteration occurs in both adipose tissues and liver, contributing 
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to insulin resistance, type 2 diabetes and NAFLD14–17. Recent studies provide convincing evidence that resi-
dent macrophages in the liver, i.e., Kupffer cells, are activated towards M1 phenotype in obesity18. Moreover, 
pro-inflammatory macrophages are also recruited to the liver under high fat diet (HFD) feeding19,20. These studies 
demonstrate that both activated M1 Kupffer cells and recruited macrophages in the liver cause hepatic inflamma-
tion and promote hepatic steatosis.
The regulatory mechanisms of macrophage phenotypes are complex and far from being characterized. Among 
other markers, iNOS and type-I arginase (Arg-I), the enzymes that are involved in L-arginine/NO metabolism, 
are associated with M1 and M2 macrophage phenotype, respectively13. A type-II arginase (Arg-II) also exists. In 
contrast to Arg-I which is constitutively and most abundantly expressed in hepatocytes21,22 and functions as a 
detoxifying enzyme in urea cycle to remove ammonia23, Arg-II is not expressed in hepatocytes but in many extra-
hepatic tissues/cells including kidney, brain, vasculature, and macrophages22,24. Moreover, Arg-II is up-regulated 
in macrophages by pro-inflammatory stimuli such as lipopolysaccharide (LPS) and associated with M1 pheno-
type25. Our recent study provides evidence demonstrating that Arg-II promotes macrophage pro-inflammatory 
responses, contributing to atherogenesis and obesity-associated insulin resistance26. Furthermore, we also showed 
that Arg-II forms a positive regulatory circuit with mTORC1-S6K1 and negatively regulates AMPK, resulting in 
functional changes of vascular cells, including eNOS-uncoupling, cell apoptosis/senescence, and impaired auto-
phagy function27–29.
Despite the beneficial effects of Arg-II deficiency on the chronic inflammatory diseases, it is to note that phar-
macological inhibition of arginase or genetic ablation of Arg-II in HFD-induced obesity mouse model yielded 
completely contradictory results on the pathology of liver steatosis as reported by the most recently published 
two studies30,31. Hence, it is important to further delineate the role of Arg-II in obesity-associated NAFLD and the 
underlying mechanisms. In this study, we demonstrate that Arg-II deficiency protects against obesity-associated 
NAFLD in mice through suppression of liver macrophage-mediated pro-inflammatory responses resulting in 
improved AMPK activation and decreased lipogenesis in hepatocytes.
Results
Reduced liver weight in obese Arg-II−/− mice fed HFD. After HFD feeding for 14 weeks, no significant 
difference in body weight and body weight gain between the WT and Arg-II−⁄− mice were observed (Fig. 1A,B). 
Figure 1. Liver weight is reduced in obese Arg-II−/− mice. Starting from 7 weeks of age, male wild-type (WT) 
and Arg-II−/− mice were fed a HFD for 14 weeks to induce obesity or maintained on normal chow diet (NC) 
as controls. (A) Body weight was measured at the start and at the end of HFD or NC feeding. (B) Weight gains 
during HFD feeding period. (C) Liver weight at the end of HFD. (D) Ratio of the liver weight and body weight 
at the end of HFD. *p < 0.05 and ***p < 0.001 between the indicated groups.
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The liver weight and the liver weight/body weight ratio were, however, significantly lower in the Arg-II−⁄− mice as 
compared to the WT mice on HFD feeding (Fig. 1C,D).
Arg-II deficiency reduces HFD–induced liver steatosis. In line with above observations, Arg-II−/− 
mice on HFD feeding displayed reduced hepatic steatosis as revealed by histomorphometric analysis of hema-
toxylin and eosin (HE) staining (Fig. 2A) and Oil Red O staining (Fig. 2B) in the liver sections, and significantly 
reduced hepatic triglyceride content when compared to the WT mice on HFD (Fig. 2C).
Arg-II deficiency suppresses hepatic lipogenic enzymes and signaling. Next, we examined the 
hepatic lipogenic signaling and enzymes. Arg-II−/− mice on HFD feeding revealed decreased activities of lipo-
genic enzymes in the liver such as G6PDH and FAS but not ME (Fig. 3A). Also the hepatic SCD-1 levels were sig-
nificantly lower in the Arg-II−/− mice as compared to the WT littermates on HFD feeding (Fig. 3B). The reduced 
SCD-1 levels in the Arg-II−/− mice were associated with increased AMPK activation as measured by enhanced 
p-AMPK levels (Fig. 3B). Furthermore, expression of SREBP-1c was significantly reduced in the liver of Arg-II−/− 
mice on HFD (Fig. 3C). No difference in S6K1 activity as monitored by S6-S235/236 level was observed between 
the WT and Arg-II−/− mice fed HFD (data not shown). The results demonstrate a role of Arg-II in hepatic lipo-
genesis linking to the development of liver steatosis induced by HFD feeding. Taking into account that inhibition 
of SCD-1 in the context of the overflow of free fatty acids coming to the liver on HFD feeding has been shown to 
cause the buildup of toxic lipids resulting in increased hepatocyte cell death and liver injury despite the decreased 
TG deposition32,33, we assessed the liver injury by monitoring plasma alanine aminotransferase (ALT) and aspar-
tate aminotransferase (AST). As shown in Fig. S1, plasma ALT and AST are significantly increased upon HFD 
feeding in both WT and Arg-II−/− mice. However, the increase in plasma ALT and AST tends to be smaller in 
obese Arg-II−/− mice as compared to obese WT mice.
Figure 2. HFD-induced hepatic steatosis is reduced in Arg-II−/− mice. Presented are images of (A) HE 
staining taken at two different magnifications. (B) Oil Red O staining in liver of WT and Arg-II−/− mice on 
either normal chow diet (NC) or high fat diet (HFD). Scale bar = 0.2 mm. (C) Liver triglyceride content. 
**p < 0.01, ***p < 0.001 between the indicated groups.
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Arg-II-deficiency enhances adiponectin levels in adipose tissue, but not in plasma and in 
liver. Taking into account that Arg-II is an extrahepatic isoform of arginase and was not detectable in WT 
mouse liver and that Arg-I expression was not affected by Arg-II-deficiency (Fig. S2), the protective effect of 
Arg-II-deficiency on HFD-induced liver steatosis must be secondary to its effect on Arg-II-expressing cells/tis-
sue. Given that adiponectin exerts its protective effects against liver steatosis through activating AMPK signaling 
pathway34 which is enhanced in Arg-II−/− mouse liver (Fig. 3B), we examined the adiponectin levels in adipose 
tissues, plasma and liver. Though the adiponectin mRNA level in epididymal adipose tissue as monitored by 
qRT-PCR is indeed significantly increased in Arg-II−/− mice (Fig. 4A), no difference in adiponectin levels was 
found in plasma or liver between WT and Arg-II−/− mice on HFD (Fig. 4B,C). No difference in weight of epididy-
mal adipose tissue was found between WT and Arg-II−/− mice on HFD either (Fig. S3). These results rule out 
the endocrine and paracrine effects of adiponectin as a mechanism for enhanced AMPK and reduced hepatic 
lipogenesis in the Arg-II−/− mice.
Arg-II-positive macrophages are increased in fatty liver. Macrophage-mediated inflammation has 
been mechanistically linked to the augmented hepatic lipogenesis in obesity17. Our previous studies demonstrate 
that Arg-II-deficiency suppresses obesity-associated systemic macrophage-mediated inflammation26. We thus 
examined the hepatic macrophage inflammation. Under HFD feeding, the number of CLEC4F positive and F4/80 
positive macrophages in the WT-liver was increased, which was prevented in Arg-II−/− mice (Fig. 5 and Fig. S4). 
Moreover, Arg-II was exclusively expressed in these cells and was enhanced on HFD feeding as demonstrated by 
immunofluorescence staining (Fig. 5). In line with these observations, the pro-inflammatory cytokine TNF-α 
was significantly lower in obese Arg-II−/− mice liver (Fig. 6). We also observed a lower IL-6, MCP-1 and CCR-2 
levels in Arg-II−/− mice liver, which statistically did not reach significance (Fig. 6). These results indicate that sup-
pression of liver steatosis in obese Arg-II−/− mice might be attributable to reduced hepatic macrophage-mediated 
inflammation.
Figure 3. Reduced lipogenic enzyme activity/expression and SREBP-1c expression, and enhanced AMPK 
signaling in obese Arg-II−/− mice. (A) Activity of malic enzyme (ME), glucose-6-phosphate-dehydrogenase 
(G6PDH) and FAS in liver from obese WT and Arg-II−/− mice. (B) Shown is immunoblotting analysis of 
SCD-1 and phosphorylated AMPK-T172 (p-AMPK) and total AMPK levels from obese WT and Arg-II−/− liver. 
Tubulin served as a loading control. Quantification of the signals is presented in the graphics below.  
(C) qRT-PCR analysis of SREBP-1c mRNA expression in liver from obese WT and Arg-II−/− mice. *p  < 0.05 
and ***p  < 0.001 vs WT-HFD.
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Suppressed production of IL-6 and TNF-α in Arg-II−/− macrophages accounts for reduced 
hepatic lipogenesis. To further confirm the above-mentioned findings, we prepared macrophages derived 
from bone marrow cells (BMM) that were isolated from WT or Arg-II−/− mice. The levels of secreted TNF-α 
and IL-6 in the BMM-conditioned medium (CM) from BMM upon LPS stimulation (100 ng/ml, 8 h) were deter-
mined. As shown in Fig. 7A, production of TNF-α and IL-6 upon LPS stimulation was significantly reduced in 
BMM from Arg-II−/− mice as compared to those from WT control animals. We then evaluated the effects of the 
CM from LPS-treated BMM on triglyceride synthesis in a murine hepatocyte cell line (AML12) in the presence 
of oleic acid (OA) that enhances hepatic triglyceride synthesis35. Remarkably, triglyceride synthesis in the hepat-
ocytes was significantly lower in the presence of Arg-II−/−-BMM-CM as compared to WT-BMM-CM (Fig. 7B), 
suggesting that the lower IL-6 and TNF-α levels released from Arg-II−/− BMM accounts for the reduced triglyc-
eride synthesis induced by Arg-II−/−-BMM-CM.
To further reinforce the above conclusion, BMM-CM was first incubated with control IgG or neutralizing 
antibodies against IL-6, TNF-α or both and then used to treat the AML12 cells in the presence of OA. Fig. 7C 
shows that anti-TNF-α or anti-IL-6 antibody alone reduced triglyceride synthesis stimulated by BMM-CM of 
WT or Arg-II−/−. The strongest suppressing effects were achieved with the combination of both antibodies, sup-
porting our conclusion drawn above.
Arg-II−/−-BMM-CM elicits enhanced AMPK activation and reduced expression of SREBP-1c and 
SCD-1 in hepatocytes. Next, we determined the effect of BMM-CM on AMPK activation, SREBP-1c and 
SCD-1 expression in AML12 hepatocytes. In line with their effects on triglyceride synthesis, AMPK activation 
as monitored by phospho-AMPK-T172 in the hepatocytes was significantly higher when the cells were treated 
with Arg-II−/−-BMM-CM as compared to the cells treated with control WT-BMM-CM (Fig. 8A). BMM-CM 
pretreated with neutralizing antibodies against IL-6 and TNF-α elicited enhanced AMPK activation (Fig. 8A). 
In accordance, the expression levels of SREBP-1c and SCD-1 in the hepatocytes were significantly lower when 
the cells were treated with Arg-II−/−-BMM-CM as compared to the cells treated with control WT-BMM-CM 
(Fig. 8B,C). Pretreatment of BMM-CM with neutralizing antibodies against both cytokines further reduced the 
expression levels of SREBP-1c and SCD-1 (Fig. 8B,C).
Discussion
In the present study, we provide both in vitro and in vivo evidences that Arg-II plays a role in HFD-induced 
liver steatosis through promoting macrophage inflammation in liver. Here we show that Arg-II−/− mice exhibit 
significantly less hepatic steatosis with decreased triglyceride content, lower hepatic weight, reduced inflamma-
tory cytokines and macrophage infiltration, which is accompanied by enhanced AMPK signaling and reduced 
expression/activity of hepatic lipogenic regulator and enzymes, including SREBP-1c, G6PDH, FAS and SCD-1, 
leading to mitigated de novo lipogenesis in the liver in vivo. The reduced liver steatosis in Arg-II−/− mice on HFD 
is in line with the results of our previous study showing an improved glucose tolerance and insulin sensitivity in 
these mice26. The decreased hepatic steatosis in the Arg-II−/− mice does not seem to be the result of decreased 
lipid delivery to the liver or increased lipid secretion from liver into the blood stream in form of lipoprotein, since 
there is no difference in plasma triglyceride levels between WT and Arg-II−/− mice fed HFD as shown in our pre-
vious study26. Our data suggest that the reduced hepatic de novo lipogenesis in the obese Arg-II−/− mice ends up 
in decreased intrahepatic triglyceride accumulation versus lipid secretion. A dissociation of plasma triglyceride 
levels from liver steatosis has been reported by numerous studies36,37. Moreover, we show that in vitro, the CM 
from Arg-II−/− macrophages elicited lower triglyceride synthesis in cultured hepatocytes in the presence of oleic 
acid, which is accompanied by enhanced AMPK signaling and suppressed lipogenic regulator/enzyme SREBP-1c 
and SCD-1 and is attributable to the reduced production of the pro-inflammatory cytokines TNF-α and IL-6 
from Arg-II−/− macrophages. Our findings thus suggest that targeting Arg-II is beneficial for obesity-associated 
NAFLD.
Figure 4. Enhanced adiponectin in fat tissue but not in plasma or liver in Arg-II−/− mice. (A) qRT-
PCR analysis of adiponectin mRNA expression in epididymal fat tissue from obese WT and Arg-II−/− mice. 
***p < 0.001 vs WT-HFD group. (B) Adiponectin level in plasma measured by ELISA. (C) qRT-PCR analysis of 
mRNA expression of adiponectin in liver tissue from obese WT and Arg-II−/− mice.
www.nature.com/scientificreports/
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Figure 5. Enhanced hepatic inflammation upon HFD in WT is associated with increased Arg-II expression 
in macrophages in liver, which is abrogated by Arg-II-deficiency. (A) Shown are representative images of 
immunostaining of the liver sections with macrophage marker CLEC4F (red) and Arg-II (green) followed by 
nuclei counterstaining with DAPI (blue). Scale bar = 50 μ m. (B) Quantification of the signal is expressed as a 
ratio of CLEC4F- or Arg-II-positive cells to tissue nuclei number. ***P < 0.001 vs WT-NC. ###P < 0.001 vs WT-
HFD.
www.nature.com/scientificreports/
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In agreement with the previous studies on Arg-I and -II expression in various tissues22,38, we could not detect 
Arg-II expression in liver from mice by immunoblotting analysis, nor Arg-II was detectable in hepatocytes by 
immunostaining. Given that Arg-II-deficiency protects mice from obesity-associated fatty liver despite undetect-
able Arg-II in hepatocytes, we postulate that the protective effects are secondary to an effect on other tissues or 
cells. Studies have provided convincing evidence showing that liver macrophages including resident Kupffer cells 
and recruited myeloid cells from circulating blood, when activated, promote hepatic inflammation and accel-
erate hepatic lipogenesis leading to lipid accumulation in the hepatocytes through release of pro-inflammatory 
cytokines17,19. A recent study by Morinaga et al. elegantly demonstrated that, in HFD-induced obesity mouse 
model, Kupffer cells become activated to express MCP-1 (although the number of Kupffer cells does not increase), 
which then recruit macrophages from blood to liver, enhancing hepatic inflammation and hepatic insulin resist-
ance20. In line with this study, we observed increased macrophages in the liver of obese WT mice, which was 
reduced in obese Arg-II−/− mice. Importantly, Arg-II is mainly expressed and markedly enhanced in hepatic 
macrophages with concomitant enhanced accumulation of macrophages in obese WT mice as demonstrated by 
immunostaining, since the immunostaining signals of Arg-II in macrophages as well as the number of CLEC4F/
Arg-II double positive or F4/80/Arg-II double positive cells are increased in the obese WT mouse liver. These 
observations are in accordance with our previous study26. Consistent with these observations, we also found 
significantly reduced TNF-α levels as well as reduced IL-6, MCP-1 and CCR-2 levels (although statistically not 
significant) in the liver of obese Arg-II−/− mice as compared to the obese WT control animals. These findings 
demonstrate that Arg-II is associated with macrophage-mediated pro-inflammatory responses, which is in agree-
ment with our previous findings that Arg-II is upregulated in macrophages of mice fed HFD and plays a caus-
ative role in promoting macrophage pro-inflammatory responses in obesity and insulin resistance26. Moreover, 
vascular inflammation and endothelial dysfunction associated with aging are protected in the Arg-II−/− mice27. 
In support of our notions, the pro-inflammatory effects of Arg-II in endotoxin-induced uveitis and in diabetic 
nephropathy have been reported39,40. All the findings demonstrate a pro-inflammatory role of Arg-II in several 
inflammation disease models. In the present study, we further demonstrate that the Arg-II−/−-BMM-CM elicits 
Figure 6. Decreased cytokine production in liver of Arg-II−/− mice. qRT-PCR analysis of mRNA expression 
of cytokines in liver tissue from WT and Arg-II−/− mice either on NC or HFD. Except for IL-6, all data are 
presented as fold change from WT-NC group, since IL-6 is not detectable in WT-NC; the data for IL-6 are 
presented as fold change from WT-HFD group. *p < 0.05, **p < 0.01, ***p < 0.001 vs WT-NC group; #p < 0.05 
vs WT-HFD group.
www.nature.com/scientificreports/
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a reduced triglyceride synthesis in the presence of oleic acid in cultured hepatocytes as compared to that of 
WT-BMM-CM, which is attributable to mitigated production of TNF-α and IL-6 from Arg-II−/−-BMM, since 
neutralizing antibody against TNF-α or IL-6 and combination of the two antibodies exhibit inhibition of triglyc-
eride accumulation in the hepatocytes. These in vitro studies using AML12 hepatocytes were aimed to reinforce 
our findings in vivo. Although it is not optimal to use this cell line, which is established from a mouse hepatocyte 
transgenic for human TGF-α , the results on triglyceride accumulation and intracellular signaling in response 
to treatment with conditioned medium from WT and Arg-II−/−-BMM are in line with the in vivo experiments 
and support our conclusion. The fact that silencing Arg-II in monocytes decreased their adhesion activity to 
endothelial cells26 suggest that this may at least in part accounts for suppressed macrophage-infiltration in liver of 
Arg-II−/− mice fed HFD. It is of great interest to further evaluate the precise mechanisms of Arg-II in regulating 
adhesion of monocytes to endothelial cells. Regarding the molecular mechanism regulating Arg-II expression 
in macrophages in obesity, evidence has been presented that hyperactive S6K1 upregulates Arg-II in cardiovas-
cular system27,28. Taking into account that HFD has been reported to activate S6K1 in various tissues41,42, it is 
attempting to speculate that S6K1 may also mediate HFD-induced increase in Arg-II expression in macrophage. 
Further experiments will be required to verify this hypothesis. Taken together, our in vivo and in vitro experi-
ments demonstrate that Arg-II deficiency protects mice from obesity-linked liver steatosis through suppression 
of macrophage-mediated hepatic inflammation.
Both mTORC1-S6K1 and AMPK pathways have been implicated in insulin resistance and lipogenesis in the 
liver in obesity at least in part through regulation of SREBP-1c gene expression and activation4–7,43. In the vascular 
cells, we showed a positive crosstalk between Arg-II and mTORC1-S6K1 as well as a negative crosstalk between 
Arg-II and AMPK pathway27–29. In the present study, we observed a higher hepatic AMPK signaling in obese 
Arg-II−/− mice as compared to the obese WT mice, whereas no difference in hepatic mTORC1-S6K1 signaling 
between the two genotypes of obese mice was detected. Taking into account that AMPK inhibits mTORC1-S6K1 
Figure 7. Suppressed production of IL-6 and TNF-α in Arg-II−/− macrophages accounts for reduced 
lipogenesis in hepatocyte AML12 cells. The serum-starved (overnight) WT- or Arg-II−/−-BMM were 
incubated in the absence or presence of 100 ng/ml LPS for 8 hours, the conditioned medium (CM) was then 
collected. (A) IL-6 and TNF-α production in CM collected from WT- or Arg-II−/−-BMMs in the absence or 
presence of LPS was evaluated by ELISA. ***p < 0.001 vs controls (-LPS), ###p < 0.001 vs WT+ LPS. (B) AML12 
hepatocytes were serum-starved for 6 hours in 0.2% bovine serum albumin (BSA)-ITS-DMEM-F-12 Ham 
medium and then incubated with CM of LPS-treated BMM from WT or Arg-II−/− mice as indicated in the 
presence of oleic acid (OA, 20 mmol/L) for 24 hours. The lipid was then extracted for measurement of the 
triglyceride content in the cells. *p < 0.05 vs WT-CM. (C) Experiment procedure is the same as in panel B, 
except that BMM-CM was pre-treated for 2 hours with control rat IgG (10 μ g/ml) or neutralizing antibodies 
anti-IL-6 (18 μ g/ml) or anti-TNF-α (0.4 μ g/ml) or anti-IL-6 (18 μ g/ml) plus anti-TNF-α prior to the addition 
to the cells. *p < 0.05, **p < 0.01, ***p < 0.001 vs (WT-BMM-CM + IgG); ##p < 0.01, ###p < 0.001 vs (Arg-II−/− 
-BMM-CM + IgG).
www.nature.com/scientificreports/
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signaling pathway44, the fact that elevated AMPK signaling in Arg-II−/− liver is not accompanied by reduced 
mTORC1-S6K1 signaling suggests that an AMPK-independent mechanism in activating mTORC1-S6K1 is dom-
inant. Moreover, these results also suggest that elevated AMPK suppresses hepatic lipogenesis and ultimately 
liver steatosis through mTORC1-S6K1-independent mechanism(s) in obese Arg-II−/− mice. Indeed, AMPK has 
been shown to suppress SREBP-1c expression and activity by directly phosphorylating SREBP-1c-S3726,7,45. Since 
Arg-II is not detectable in the liver of WT mice fed either NC or HFD, the difference in hepatic AMPK signa-
ling between WT and Arg-II−/− does not result from the crosstalk between Arg-II and AMPK as observed in 
vascular cells29. Adiponectin, an important adipocyte-derived factor that has inhibitory effects on insulin resist-
ance, hepatic steatosis and inflammation46, is a well-known endogenous AMPK activator47. However, a role of 
adiponectin in activation of AMPK in the liver of obese Arg-II−/− mice can be excluded, since no differences in 
circulating or hepatic levels of adiponectin were evident between obese WT and Arg-II−/− mice, although adi-
ponectin level was significantly higher in adipose tissue of Arg-II−/− mice than the WT controls. Since there is no 
difference in epididymal fat weight between the obese Arg-II−/− and WT mice, this suggests that the discrepancy 
of the difference in adiponectin levels in adipose tissue and plasma between the two genotypes is not a conse-
quence of a decrease in fat mass in Arg-II−/− mice. It rather indicates an increased local paracrine/autocrine but 
not endocrine secretion of adiponectin from adipose tissue into the circulation in Arg-II−/− mice. The fact that 
suppressed macrophage-mediated hepatic inflammation accounts for the reduced lipogenesis and liver steatosis 
in Arg-II−/− mice prompted us to hypothesize that the enhanced AMPK in hepatocytes is attributable to the 
Figure 8. CM from Arg-II−/−-BMM elicits increased AMPK signaling and decreased SREPBP-1c and 
SCD-1 in hepatocytes. Experiment procedure is the same as in Fig. 7B, except that (A) AML12 hepatocyte 
cell lysates were prepared for immunoblotting analysis of AMPK activation. Quantification of the signals is 
presented below. (B,C) RNA was extracted for qRT-PCR analysis of mRNA expression of SREBP-1c and SCD-1. 
For all the panels *p < 0.05, **p < 0.01, ***p < 0.001 between the indicated groups. Neutral. Abs means 
neutralizing antibodies. IgG was used as control (-) for neutralizing antibodies. (D) Schematic illustration of the 
major findings of this study.
www.nature.com/scientificreports/
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reduced hepatic inflammation. The hypothesis is confirmed by our in vitro experiments showing that hepatocytes 
treated with the Arg-II−/−-BMM-CM exhibits higher AMPK activation, lower mRNA levels of SREBP-1c and 
SCD-1 as compared to the cells treated WT-BMM-CM, which could be further improved by neutralizing anti-
bodies against IL-6 and TNF-α .
There is an increase in serum liver enzymes ALT and AST in Arg-II−/− mice fed HFD, but this increase is actu-
ally smaller than those from WT-HFD group, although it does not reach statistical significance. Together with the 
results of hepatic steatosis and inflammation, these results demonstrate that Arg-II deficiency reduces but does 
not abolish liver injury in HFD-induced obesity. Extensive studies have shown that inhibition of SCD-1 in the 
context of the overflow of free fatty acids coming to the liver on HFD feeding causes the build-up of toxic lipids 
resulting in increased hepatocyte cell death and liver injury even there is decreased triglyceride deposition32,33. 
However, we show here that significantly reduced SCD-1 in the liver of obese Arg-II−/− mice as compared to that 
of obese WT mice does not lead to an accelerated liver injury while suppressing hepatic triglyceride synthesis, 
suggesting that the decreased hepatic SCD-1 is not necessarily accompanied by an exacerbation of liver damage. 
It remains elusive what is the mechanism that prevents hepatocyte damage from a decreased hepatic SCD-1 level 
under certain conditions such as in Arg-II−/− mice.
During preparation of this manuscript, two studies on the role of arginase in obesity-associated liver steatosis 
with opposite conclusions were reported30,31. In the study of Moon et al.30, using arginase inhibitor nor-NOHA 
that is an isoform non-specific inhibitor, the authors showed some similar findings to the ones we obtained 
with Arg-II−/− mice including reduced liver steatosis and liver triglyceride content, reduced expression of 
SCD-1 as well as elevated AMPK signaling. By demonstrating the direct inhibitory effect of nor-NOHA on oleic 
acid-induced triglyceride synthesis with concurrent increase in NO production and AMPK signaling in HepG2 
hepatocytes in vitro, they conclude that arginase inhibition reduces obesity-induced hepatic lipid abnormality 
most likely attributable to the inhibition of Arg-I. However, this mechanism unlikely accounts for the beneficial 
effect of Arg-II deficiency in obesity-induced liver steatosis in our study, since Arg-II is not expressed in hepato-
cytes and no change in Arg-I level or total arginase activity in liver of Arg-II−/− mice was observed. In contrast to 
this study and also to our present study, Navarro et al. using Arg-II−/− mice, reported an increased macrophage 
inflammation and liver steatosis accompanied by an increase in de novo hepatic lipogenesis in Arg-II−/− mice on 
HFD feeding. Although reasons of the discrepancy between the studies are not clear, yet, the following points 
could be taken into consideration. In the study by Navarro et al. all the control C57BL/6J mice were purchased 
from Jackson laboratory, whereas the Arg-II−/− mice were obtained from another laboratory. In our study, we 
used offspring of WT/WT and Arg-II−/−/Arg-II−/− derived from heterozygous breeding. Evidence has been pre-
sented that multiple substrains will be created within an inbred strain that became increasingly more genetically 
divergent through generations of independent inbreeding48. Although Arg-II−/− mice have been backcrossed to 
C57BL/6J mice over 10 generations, which is considered as congenic to C57BL/6J, the independent breeding of 
the mice may lead to creation of a substrain that became genetically divergent from C57BL/6J mice purchased 
from Jackson Laboratory. It could thus not be excluded that the difference in macrophage inflammation associ-
ated with liver steatosis phenotype observed in their study is consequence of other genetic differences. Moreover, 
the numbers of animals used were not indicated throughout their report. If the animal number used in the study 
is too small, the results could be biased. In addition, Arg-II is highly expressed in the liver of WT type mice in 
their report, which is in contrast to studies published by other groups including our present study22,38. It is puz-
zling that Arg-II is even detectable in the Arg-II−/− liver, although it is at lower levels as compared to the WT 
mice. This raises concerns about the genetic modified mouse model used in their study. Nevertheless, despite 
very few reported studies on the role of Arg-II in macrophage inflammatory responses, our work showing the 
pro-inflammatory role of Arg-II in macrophages is in accordance with several other studies25,39,40. Finally, our pre-
vious studies also provide convincing evidence showing a protective and healthier metabolic and aging phenotype 
of Arg-II−/− mice on HFD or high cholesterol diet26–29.
In summary, our present study demonstrates that targeting Arg-II protects mice from HFD-induced liver 
steatosis through suppression of macrophage inflammation and suppression of the release of TNF-α and IL-6, 
which leads to improved AMPK activation, resulting in inhibition of SREBP-1c and ultimately the suppression of 
lipogenic enzymes and inhibition of hepatic lipogenesis (Fig. 8D). Our findings implicate that targeting Arg-II is 
beneficial for obesity-associated NAFLD.
Methods
Materials. All chemicals including those used for immunoblotting and anti-tubulin (T5168) were obtained 
from Sigma (Buchs, Switzerland); anti-phospho-AMPK (Thr-172) (2535S), anti-AMPKα (2793S), and anti-
SCD-1 (2438S) were from Cell Signaling (Allschwil, Switzerland); anti-Arg-II (sc-20151) and anti-CLEC4F 
(SC-242467) were from Santa Cruz (Nunningen, Switzerland). Anti-F4/80 (MCA497G) was from AbD Serotec 
(Dusseldorf, Germany). Bio-Rad DCTM protein assay kit was from Bio-Rad (Basel, Switzerland); Alexa Fluor680-
conjugated anti-mouse IgG (A21057) was from Molecular Probes ⁄ Invitrogen (Lucerne, Switzerland); IRDye800-
conjugated anti-rabbit IgG (926-32211) were from LI-COR Biosciences (Bad Homburg, Germany). Neutralizing 
rat anti-mouse-IL-6 (BMS178) and control rat IgG1 (16-4301-85) were from eBioscience (Vienna, Austria). 
Neutralizing anti-TNF-α (AB-410-NA) was from R&D systems (Minneapolis, USA). All reagents for the activ-
ity assay of lipogenic enzymes including ME, G6PDH and FAS were kindly provided by Jean-Francois Cajot 
(University of Fribourg, Switzerland).
Animals. The breeding and genotyping of wild type (WT) and Arg-II-deficient mice (Arg-II−⁄−) were as pre-
viously described26,49. Starting at the age of 7 weeks, the male WT and Arg-II−/− mice were given free access for 
14 weeks to a HFD (energy content: 55% fat, 21% protein, and 24% carbohydrate, Harlan Teklad TD 93075) 
and maintained on a 12-h light-dark cycle and tap water. After 14 weeks of HFD, the animals were sacrificed 
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after intraperitoneal anesthesia with xylazine (10 mg kg−1body weight) and ketamine (100 mg kg−1 body weight). 
Blood and liver tissues were then collected for histological analysis or snap-frozen in liquid nitrogen and kept at 
− 80 °C until processed. Animal work was approved by the Ethical Committee of Veterinary Office of Fribourg 
(number 174/07), Switzerland and was performed in compliance with guidelines on animal experimentation at 
our institution.
Cell Culture. The mouse AML12 hepatocytes cell line from American Type Culture Collection were main-
tained in DMEM/F-12 Ham medium supplemented with 10% fetal bovine serum (FBS) and human insulin- 
transferrin- sodium selenite (ITS) media supplement. Treatments were carried out after 6 hours starvation in 
0.2% bovine serum albumin (BSA)-ITS-DMEM-F-12 Ham.
Bone marrow-derived macrophages (BMM) were prepared from bone marrow-derived cells by incubation 
with 10% HIFBS-RPMI, supplemented with 20% of L929-conditioned medium containing macrophage colony–
stimulating factor, for 6 to 7 days to induce differentiation as described previously26. After 6 hours starvation in 
0.2% BSA–RPMI, cells were either untreated or treated with LPS (100 ng/ml, 8 h). The conditional medium (CM) 
was then collected for further study.
Enzyme-Linked Immunosorbent Assay (ELISA). The plasma adiponectin levels was evaluated accord-
ing to the manufacturer’s instruction with the Adiponectin ELISA Kit (Assaypro LLC, Saint Charles, Missouri, 
USA), the IL-6 and TNF-α level in BMM-CM were with the ELISA MAXTM Deluxe kit from BioLegend (Lucerna 
Chem AG, Luzern, Switzerland).
Real-Time Quantitative Reverse Transcription Polymerase Chain Reaction Analysis 
(qRT-PCR). Total RNA was extracted from tissues with Trizol Reagent (Molecular Research Center, Inc., 
Cincinnati, OH, USA) following the supplier’s protocol. The mRNA expression was evaluated by two-step 
qRT-PCR analysis as described previously26. The mRNA expression levels of all genes were normalized to the 
reference gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The primer sequences are as follows:
mIL-6F: GACAACCACGGCCTTCCCTA ;
mIL-6R: GCCTCCGACTTGTGAAGTGGT.
mTNF-α F: GGCAGGTCTACTTTGGAGTCATTGC;
mTNF-α R: ACATTCGAGGCTCCAGTGAATTCGG.
mMCP-1F: AGCACCAGCCAACTCTCAC;
mMCP-1R: TCTGGACCCATTCCTTCTTG.
mAdiponectinF: TGTTCCTCTTAATCCTGCCCA;
mAdiponectinR: CCAACCTGCACAAGTTCCCTT.
mGAPDHF: ACCCAGAAGACTGTGGATGG;
mGAPDHR: ACACATTGGGGGTAGGAACA.
mSREBP-1cF: AAGCAAATCACTGAAGGACCTGG
mSREBP-1cR: AAAGACAAGGGGCTACTCTGGGAG
mSCD-1F: TTCTTACACGACCACCACCA
mSCD-1R: GCAGGAGGGAACCAGTATGA
Interaction between BMM and Hepatocytes in vitro. After 6 h starvation, AML12 hepatocytes were 
changed to BMM-CM and incubated in presence of oleic acid (OA, 20 mmol/L) for 24 h till the extraction.
For antibody blocking studies, the BMM-CM was incubated with control IgG or neutralizing anti-IL-6 (18 μ g/ml), 
anti-TNF-α (0.4 μ g/ml) or combination of anti-IL-6 and anti-TNF-α for 2h prior to the addition to the 
AML12 cells as described above.
Measurement of Triglyceride Levels in Cultured Hepatocytes and in Liver Tissues. The lipid 
extraction and triglyceride measurement in cultured hepatocytes were carried out with the triglyceride quan-
tification kit (BioVision, Mountain View, CA) according to the manufacturer’s instructions. Measurement of 
liver triglyceride was performed as previously described50. Briefly, Livers were homogenized and the hepatic 
triglyceride was extracted by digesting 100–300 mg liver tissues overnight at 55 °C in 350 μ l ethanolic potassium 
hydroxide (2:1 v/v of 100% ethanol and 30% potassium hydroxide). Samples were neutralized with water:ethanol 
(1:1 v/v; total volume of 1 ml). After centrifugation (8000 g, 5 min), 1 ml of supernatant was collected and brought 
to 1.2 ml volume with water:ethanol (1:1). Then, 200 μ l was removed and proceeded to saponification with 215 μ l 
of 1 mol/L MgCl2 by vortexing and incubating on ice for 10 min. Saponified liver extracts (the upper phase) 
were separated by centrifugation and kept frozen at − 80 °C. After thawing the samples, triglyceride quantity was 
determined by an enzymatic colorimetric assay (TRIGL:ACN 781) on Roche/Hitachi cobas c system (Roche, 
Switzerland). The color intensity of the red dye stuff formed was proportional to the triglyceride concentration 
(mmol/L) and was determined at 505 nm.
Lipogenic Enzyme Activity Assay. To assess the activities of the lipogenic enzymes including ME, G6PDH 
and FAS in liver, liver tissues were homogenized in extraction buffer consisting of 250 mmol/L sucrose, 50 mmol/L 
Tris/HCl pH 7.3 and 30 mmol/L mercaptoethanol, and centrifuged at 13000 rpm for 10 min at 4 °C. Protein concen-
trations of the supernatants were determined by Bradford assay solution from Applichem (A6932, 0500).
The activity of ME and G6PDH was determined spectrophotometrically by measuring the increase in absorb-
ance at 340 nm resulted from the reduction of NADP as previously described51,52, whereas FAS activity was deter-
mined spectrophotometrically by measuring the decrease in absorbance at 340 nm resulted from the oxidation of 
NADPH as described previously53. All the enzyme activity assays were run at 37 °C in duplicate in a prewarmed 
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Bio-Rad (Model 680) microplate Spectrophotometer. Absorbance at 340 nm (37 °C) was measured using software 
programmed for a kinetic read sequence of 1 min intervals over 10 minutes for ME and G6PDH, every 2 min over 
20 minutes for FAS. The enzyme activity was calculated by obtaining the Δ A340 nm/minute with the maximum 
and the minimum value using 5 data points in the linear range with respect to time and to sample concentration. 
Data are presented as fold change in the enzyme activity.
Immunoblotting Analysis. Cell lysate preparation, SDS-PAGE, immunoblotting, antibody incubation and 
signal detection were performed as described previously26. Quantification of the signals was performed using 
NIH Image 1.62 software.
Hematoxylin and eosin (HE) and Oil Red O Staining. Liver tissues embedded in paraffin or frozen in 
OCT compounds were cut at 7 μ m, then stained with HE or oil red O, respectively, as described previously26,54.
Tissue Immunofluorescence Staining and Confocal Microscopy. Preparation of paraffin-embedded 
sections (7 μ m) and immunostaining were performed as described previously26. The immunofluorescence signals 
were visualized under LEICA’s DIM6000 Confocal microscope. The fluorescence signals were quantified with 
NIH IMAGE J and results are presented as the ratio of F4/80, Arg-II, CLEC4F to DAPI-positive nucleus.
Measurement of blood parameters. Measurement of plasma alanine aminotransferase (ALT) and aspar-
tate aminotransferase (AST) were performed by Laboratory HFR, Hospital Fribourgeois. Plasma adiponectin was 
determined by ELISA.
Statistics. Data are given as mean± SEM. In all experiments, n represents the number of animals. Statistical 
analysis was performed with unpaired t test or ANOVA with Dunnett or Bonferroni post-test. Differences in 
mean values were considered significant at p ≤ 0.05.
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